Mostrar el registro sencillo del ítem

dc.contributor.authorMedina-Cáliz, Inmaculada 
dc.contributor.authorSanabria-Cabrera, Judith Adriana 
dc.contributor.authorVillanueva-Paz, Marina
dc.contributor.authorAukštikalnė, Lauryna
dc.contributor.authorStephens, Camilla
dc.contributor.authorRobles-Díaz, María Mercedes 
dc.contributor.authorPinazo-Bandera, José M.
dc.contributor.authorGarcía-Cortés, Miren 
dc.contributor.authorConde, Isabel
dc.contributor.authorSoriano, German
dc.contributor.authorBessone, Fernando
dc.contributor.authorHernandez, Nelia
dc.contributor.authorNunes, Vinicius
dc.contributor.authorParana, Raymundo
dc.contributor.authorLucena-González, María Isabel 
dc.contributor.authorAndrade, Raúl J.
dc.contributor.authorAlvarez-Alvarez, Ismael
dc.contributor.authorNiu, Hao
dc.date.accessioned2024-01-11T12:06:52Z
dc.date.available2024-01-11T12:06:52Z
dc.date.issued2023-12-05
dc.identifier.citationMedina-Cáliz, I., Sanabria-Cabrera, J., Villanueva-Paz, M. et al. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. Arch Toxicol 98, 303–325 (2024). https://doi.org/10.1007/s00204-023-03630-0es_ES
dc.identifier.urihttps://hdl.handle.net/10630/28660
dc.description.abstractIdiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n = 881). DILI-DRESS cases were younger (47 vs. 53 years, respectively; p = 0.042) and presented more frequently with cholestatic/mixed damage (p = 0.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04–1.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11–69.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.es_ES
dc.description.sponsorshipFunding for open access publishing: Universidad Málaga/CBUA. This work was supported by grants from the Instituto de Salud Carlos III, cofounded by Fondo Europeo de Desarrollo Regional (FEDER) (contract numbers: PI21/01248, PI19-00883, PT20/00127, UMA18-FEDERJA-194, PY18-3364), and grants from Consejería de Salud de Andalucía cofounded by FEDER (contract numbers: PEMP-0127-2020, PI-0310-2018) and Agencia Española del Medicamento y Productos Sanitarios. M Villanueva-Paz and I Alvarez-Alvarez hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). J Sanabria-Cabrera holds a Juan Rodés research contract from the National System of Health, ISCIII (JR21/00066). JM Pinazo-Bandera holds a Río Hortega research contract from the National System of Health, ISCIII (CM21/00074). H Niu holds a postdoctoral research contract funded by Junta de Andalucía (POSTDOC_21_00780). SCReN and CIBERehd are funded by ISCIII. This publication is based on work from COST Action CA17112—Prospective European Drug-Induced Liver Injury Network, supported by COST (European Cooperation in Science and Technology); www.cost.eu. The funding sources have no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHígado - Enfermedadeses_ES
dc.subject.otherDrug-induced liver injuryes_ES
dc.subject.otherDrug reaction with eosinophilia and systemic symptomses_ES
dc.subject.otherSevere cutaneous adverse reactiones_ES
dc.subject.otherHepatotoxicityes_ES
dc.subject.otherHypersensitivity featureses_ES
dc.titleCharacterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registrieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doi10.1007/s00204-023-03630-0
dc.rights.ccAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional